Two experts discuss the role immunomodulatory drugs (IMiDs) play in the current treatment landscape for relapsed/refractory multiple myeloma and how they can be used effectively.
EP. 1: RRMM: An Overview
Joshua Richter, MD, and Jonathan L. Kaufman, MD, define and provide a basic understanding of relapsed/refractory multiple myeloma (RRMM).
EP. 2: IMiDs and Triplet Regimens in MM and RRMM Therapy
Dr Jonathan L. Kaufman discusses the role immunomodulatory drugs (IMiDs) play within triplet regimens for patients with RRMM.
EP. 3: What Factors Into IMiDs Treatment Selection for Patients With RRMM?
Drs Kaufman and Richter outline important considerations physicians should be aware of when selecting IMiD therapy for a patient with RRMM.
EP. 4: Preferred IMiDs Regimens Based on Line of Therapy
Two experts highlight their preferred treatment options for RRMM based on each line of therapy the patient will need.
EP. 5: Using Lenalidomide and Pomalidomide in RRMM Management
Dr Richter explains which patients would benefit the most from using lenalidomide vs pomalidomide, while Dr Kaufman calls attention to clinical trials that support the use of pomalidomide in RRMM therapy.
EP. 6: Ways Institutions Can Support RRMM Treatment Selection
Two practicing physicians discuss clinical pathways and decision-making tactics used at their respective institutions for RRMM management.
EP. 7: How Do IMiDs Fare In Comparison With Emerging RRMM Treatment Options?
Drs Joshua Richter and Jonathan L. Kaufman consider where IMiDs fall in the RRMM treatment landscape in comparison with emerging treatment options, such as bispecific antibodies and CAR T-cell therapy.
EP. 8: Improving Payer Education on RRMM Therapy
Professional experts offer suggestions on how payers can be further educated on RRMM treatment.
EP. 9: Discussing The Future of the RRMM Treatment Landscape
Drs Richter and Kaufman conclude by discussing future promising developments in RRMM therapy.
2 Clarke Drive Cranbury, NJ 08512